{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:17:12Z","timestamp":1791400632129,"version":"4.3.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Elevated expression of anti-apoptotic Bcl-2 family proteins have been linked to a poor survival rate of patients with Follicular Lymphoma (FL). This prompted us to evaluate a very potent non-peptidic Small-Molecule Inhibitor (SMI) targeting Bcl-2 family proteins, Apogossypolone (ApoG2) using follicular small cleaved cell lymphoma cell line (WSU-FSCCL) and cell isolated from lymphoma patients. ApoG2 inhibited the growth of WSU-FSCCL significantly with a 50% growth inhibition of cells (IC<jats:sub>50<\/jats:sub>) of 109 nM and decreased cell number of fresh lymphoma cells. ApoG2 activated caspases-9, -3, and -8, and the cleavage of Poly (ADP-ribose) polymerase (PARP) and Apoptosis Inducing Factor (AIF). In the WSU-FSCCL-SCID xenograft model, ApoG2 showed a significant anti-lymphoma effect, with %ILS of 84% in the intravenous and 63% in intraperitoneal treated mice. These studies suggest that ApoG2 can be an effective therapeutic agent against FL.<\/jats:p>","DOI":"10.1186\/1476-4598-7-20","type":"journal-article","created":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T19:13:51Z","timestamp":1203016431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model"],"prefix":"10.1186","volume":"7","author":[{"given":"Alan A","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Aboukameel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayad","family":"Al-Katib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi M","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,14]]},"reference":[{"issue":"7","key":"311_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/00152193-200507000-00051","volume":"35","author":"B Rogers","year":"2005","unstructured":"Rogers B: Looking at lymphoma and leukemia. Nursing. 2005, 35 (7): 56-63; quiz 63-4.","journal-title":"Nursing"},{"issue":"2","key":"311_CR2","first-page":"213","volume":"19","author":"AK Ganti","year":"2005","unstructured":"Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO: Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park). 2005, 19 (2): 213-28; discussion 228, 233-6, 239.","journal-title":"Oncology (Williston Park)"},{"issue":"33","key":"311_CR3","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005, 23 (33): 8447-8452.","journal-title":"J Clin Oncol"},{"issue":"10","key":"311_CR4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/cncr.22649","volume":"109","author":"S Sacchi","year":"2007","unstructured":"Sacchi S, Pozzi S, Marcheselli L, Bari A, Luminari S, Angrilli F, Merli F, Vallisa D, Baldini L, Brugiatelli M: Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer. 2007, 109 (10): 2077-2082.","journal-title":"Cancer"},{"issue":"25","key":"311_CR5","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","volume":"24","author":"OW Press","year":"2006","unstructured":"Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI: Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006, 24 (25): 4143-4149.","journal-title":"J Clin Oncol"},{"issue":"10","key":"311_CR6","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A: Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006, 108 (10): 3295-3301.","journal-title":"Blood"},{"issue":"10","key":"311_CR7","first-page":"1748","volume":"9","author":"S Raghoebier","year":"1995","unstructured":"Raghoebier S, Broos L, Kramer MH, van Krieken JH, Kluin-Nelemans JC, van Ommen GJ, Kluin P: Histological conversion of follicular lymphoma with structural alterations of t(14;18) and immunoglobin genes. Leukemia. 1995, 9 (10): 1748-1755.","journal-title":"Leukemia"},{"issue":"12","key":"311_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/molehr\/4.12.1099","volume":"4","author":"A Basu","year":"1998","unstructured":"Basu A, Haldar S: The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod. 1998, 4 (12): 1099-1109.","journal-title":"Mol Hum Reprod"},{"issue":"7","key":"311_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMcibr067155","volume":"356","author":"LM Staudt","year":"2007","unstructured":"Staudt LM: A closer look at follicular lymphoma. N Engl J Med. 2007, 356 (7): 741-742.","journal-title":"N Engl J Med"},{"issue":"13 Suppl 10","key":"311_CR10","first-page":"25","volume":"18","author":"RJ Klasa","year":"2004","unstructured":"Klasa RJ: Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Oncology (Williston Park). 2004, 18 (13 Suppl 10): 25-31.","journal-title":"Oncology (Williston Park)"},{"issue":"6580","key":"311_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/381335a0","volume":"381","author":"SW Muchmore","year":"1996","unstructured":"Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW: X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature. 1996, 381 (6580): 335-341.","journal-title":"Nature"},{"issue":"44","key":"311_CR12","doi-asserted-by":"publisher","first-page":"27886","DOI":"10.1074\/jbc.272.44.27886","volume":"272","author":"M Aritomi","year":"1997","unstructured":"Aritomi M, Kunishima N, Inohara N, Ishibashi Y, Ohta S, Morikawa K: Crystal structure of rat Bcl-xL. Implications for the function of the Bcl-2 protein family. J Biol Chem. 1997, 272 (44): 27886-27892.","journal-title":"J Biol Chem"},{"issue":"3","key":"311_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.onc.1208225","volume":"24","author":"D Yin","year":"2005","unstructured":"Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, Koeffler HP: Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene. 2005, 24 (3): 344-354.","journal-title":"Oncogene"},{"issue":"1","key":"311_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-4598-4-13","volume":"4","author":"RM Mohammad","year":"2005","unstructured":"Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A: Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther. 2005, 4 (1): 13-21.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"311_CR15","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1021\/jm060460o","volume":"49","author":"G Wang","year":"2006","unstructured":"Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, Shangary S, Qiu S, Gao W, Yang D, Meagher J, Stuckey J, Krajewski K, Jiang S, Roller PP, Abaan HO, Tomita Y, Wang S: Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006, 49 (21): 6139-6142.","journal-title":"J Med Chem"},{"issue":"7","key":"311_CR16","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-06-1574","volume":"13","author":"RM Mohammad","year":"2007","unstructured":"Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A: Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res. 2007, 13 (7): 2226-2235.","journal-title":"Clin Cancer Res"},{"key":"311_CR17","volume-title":"AACR","author":"R Mohammad Young, D.,","year":"2006","unstructured":"Mohammad R: ApoG2, a potent, non-toxic small-molecule inhibitor of Bcl-2 family: A preclinical trial in lymphoma. AACR. 2006"},{"issue":"1","key":"311_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0165-4608(93)90132-6","volume":"70","author":"RM Mohammad","year":"1993","unstructured":"Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, al-Katib A: A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet. 1993, 70 (1): 62-67.","journal-title":"Cancer Genet Cytogenet"},{"issue":"6718","key":"311_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/17135","volume":"397","author":"SA Susin","year":"1999","unstructured":"Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G: Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999, 397 (6718): 441-446.","journal-title":"Nature"},{"issue":"15","key":"311_CR20","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/jnci\/92.15.1240","volume":"92","author":"FD Groves","year":"2000","unstructured":"Groves FD, Linet MS, Travis LB, Devesa SS: Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000, 92 (15): 1240-1251.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"311_CR21","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.leukres.2006.01.014","volume":"30","author":"C Schmitt","year":"2006","unstructured":"Schmitt C, Grundt A, Buchholtz C, Scheuer L, Benner A, Hensel M, Ho AD, Leo E: One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2\/IgH positive cells: Is the end of molecular monitoring near?. Leuk Res. 2006, 30 (12): 1563-1568.","journal-title":"Leuk Res"},{"issue":"4","key":"311_CR22","first-page":"1277","volume":"8","author":"R Mohammad","year":"2002","unstructured":"Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A: Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma. Clin Cancer Res. 2002, 8 (4): 1277-1283.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"311_CR23","first-page":"207","volume":"2","author":"MR Smith","year":"1995","unstructured":"Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, al-Katib A: Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther. 1995, 2 (3): 207-212.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"311_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1365-2141.2004.05239.x","volume":"127","author":"J Ramanarayanan","year":"2004","unstructured":"Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS: Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol. 2004, 127 (5): 519-530.","journal-title":"Br J Haematol"},{"issue":"8","key":"311_CR25","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/sj.cdd.4401937","volume":"13","author":"D Zhai","year":"2006","unstructured":"Zhai D, Jin C, Satterthwait AC, Reed JC: Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ. 2006, 13 (8): 1419-1421.","journal-title":"Cell Death Differ"},{"issue":"1","key":"311_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/cbic.200600305","volume":"8","author":"Z Zhang","year":"2007","unstructured":"Zhang Z, Jin L, Qian X, Wei M, Wang Y, Wang J, Yang Y, Xu Q, Xu Y, Liu F: Novel Bcl-2 inhibitors: Discovery and mechanism study of small organic apoptosis-inducing agents. Chembiochem. 2007, 8 (1): 113-121.","journal-title":"Chembiochem"},{"issue":"4","key":"311_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/jm061152t","volume":"50","author":"M Bruncko","year":"2007","unstructured":"Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC, Nimmer PM, Oltersdorf T, Park CM, Petros AM, Shoemaker AR, Song X, Wang X, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Elmore SW: Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem. 2007, 50 (4): 641-662.","journal-title":"J Med Chem"},{"key":"311_CR28","volume-title":"Leuk Res","author":"L Oliver","year":"2007","unstructured":"Oliver L, Mahe B, Gree R, Vallette FM, Juin P: HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells. Leuk Res. 2007"},{"issue":"3","key":"311_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.leukres.2005.08.022","volume":"30","author":"J Skommer","year":"2006","unstructured":"Skommer J, Wlodkowic D, Matto M, Eray M, Pelkonen J: HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res. 2006, 30 (3): 322-331.","journal-title":"Leuk Res"},{"issue":"2","key":"311_CR30","first-page":"768","volume":"44","author":"GP Tuszynski","year":"1984","unstructured":"Tuszynski GP, Cossu G: Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res. 1984, 44 (2): 768-771.","journal-title":"Cancer Res"},{"issue":"4","key":"311_CR31","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1210\/jc.76.4.1019","volume":"76","author":"MR Flack","year":"1993","unstructured":"Flack MR, Pyle RG, Mullen NM, Lorenzo B, Wu YW, Knazek RA, Nisula BC, Reidenberg MM: Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab. 1993, 76 (4): 1019-1024.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"311_CR32","first-page":"533","volume":"28","author":"M Bayes","year":"2006","unstructured":"Bayes M, Rabasseda X, Prous JR: Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006, 28 (8): 533-591.","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"6","key":"311_CR33","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/BF00685601","volume":"30","author":"RC Stein","year":"1992","unstructured":"Stein RC, Joseph AE, Matlin SA, Cunningham DC, Ford HT, Coombes RC: A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol. 1992, 30 (6): 480-482.","journal-title":"Cancer Chemother Pharmacol"},{"key":"311_CR34","first-page":"98th AACR Annua","volume-title":"Abstract","author":"LY Zhang Y Min P, Zha","year":"2007","unstructured":"Zhang Y LY: A novel pan inhibitor of Bcl-2 and Mcl-1 apogossypolone (ApoG2) with superior stability and improved activity against human leukemia and lymphoma. Abstract. 2007, 98th AACR Annual Meeting, 2007 Los Angeles, CA-"},{"issue":"1","key":"311_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"V Del Gaizo Moore","year":"2007","unstructured":"Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007, 117 (1): 112-121.","journal-title":"J Clin Invest"},{"issue":"2 Pt 1","key":"311_CR36","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1158\/1078-0432.CCR-06-1526","volume":"13","author":"S Trudel","year":"2007","unstructured":"Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y, Reece D, Paterson J, Wang D, Wen XY: The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res. 2007, 13 (2 Pt 1): 621-629.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"311_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1083\/jcb.144.2.281","volume":"144","author":"EA Slee","year":"1999","unstructured":"Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ: Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol. 1999, 144 (2): 281-292.","journal-title":"J Cell Biol"},{"issue":"13","key":"311_CR38","doi-asserted-by":"publisher","first-page":"9303","DOI":"10.1074\/jbc.275.13.9303","volume":"275","author":"D Tang","year":"2000","unstructured":"Tang D, Lahti JM, Kidd VJ: Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem. 2000, 275 (13): 9303-9307.","journal-title":"J Biol Chem"},{"issue":"7042","key":"311_CR39","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005, 435 (7042): 677-681.","journal-title":"Nature"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-7-20.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T01:47:52Z","timestamp":1630460872000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-7-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,14]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-7-20","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,14]]},"assertion":[{"value":"28 November 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"20"}}